Summit Therapeutics (SMMT) has had the highest return this decade by a large-cap US stock in the Biotechnology Industry, returning 1,181.3%.
| ASSET | DECADE | % RETURN |
|---|---|---|
Summit Therapeutics (SMMT) | 2020s | 1,181.25% |
Insmed (INSM) | 2020s | 490.45% |
United Therapeutics (UTHR) | 2020s | 396.6% |
Natera (NTRA) | 2020s | 384.08% |
argenx NV ADR (ARGX) | 2020s | 355.25% |
Alnylam Pharmaceuticals (ALNY) | 2020s | 296.62% |
AbbVie (ABBV) | 2020s | 214.48% |
BioNTech SE (BNTX) | 2020s | 179.02% |
Exelixis (EXEL) | 2020s | 119.71% |
Gilead Sciences (GILD) | 2020s | 117.27% |
BeiGene (ONC) | 2020s | 96.33% |
Vertex Pharmaceuticals (VRTX) | 2020s | 71% |
Regeneron Pharmaceuticals (REGN) | 2020s | 53.29% |
Roivant Sciences (ROIV) | 2020s | 40% |
Ascendis Pharma A-S (ASND) | 2020s | 37.53% |
Amgen (AMGN) | 2020s | 37.25% |
Neurocrine Biosciences (NBIX) | 2020s | 35.81% |
Moderna (MRNA) | 2020s | 32.24% |
Genmab A-S (GMAB) | 2020s | 30.95% |
Haleon (HLN) | 2020s | 19.41% |
Incyte (INCY) | 2020s | -3.16% |
Biomarin Pharmaceutical (BMRN) | 2020s | -36.74% |
Biogen (BIIB) | 2020s | -53.97% |
Large-cap stocks are treated as having a market cap of $10B+.
